New molecular entity
Development and Regulatory status
Phase III Clinical Trials
Third generation, tripeptide, glutamate modulator - reduces presynaptic glutamate release altering GABAergic neurotransmission and BDNF.
AD is the most common form of dementia. It is estimated to affect 520,000 people in the UK.